论文部分内容阅读
目的:探讨非ST段抬高型急性冠脉综合征中盐酸替罗非班的应用效果。方法:以随机均分的方式把本院在2013年6月至2015年9月接收的80例非ST段抬高型急性冠脉综合征患者分为对照组和研究组各40例,两组患者均采取常规治疗,在该基础上研究组加用盐酸替罗非班,观察和比较两组患者治疗后不良反应的发生与不良心血管事件的发生。结果:研究组治疗15 d、30 d后主要不良心血管事件发生率和对照组相比明显要低(P<0.05)。两组不良反应发生率比较无显著差异(P>0.05)。结论:基于常规治疗对非ST段抬高性急性综合征患者加用盐酸替罗非班,安全可靠,可降低不良心血管事件的发生率,且不良反应少,使用价值较高,建议应用于临床中。
Objective: To investigate the application effect of tirofiban hydrochloride in non-ST segment elevation acute coronary syndrome. Methods: A total of 80 patients with non-ST-segment elevation acute coronary syndrome received by our hospital from June 2013 to September 2015 were randomly divided into control group and study group, 40 cases in each group. Two groups The patients were treated routinely, on the basis of the study group plus tirofiban hydrochloride, observed and compared two groups of patients after treatment of adverse reactions and adverse cardiovascular events. Results: The incidence of major adverse cardiovascular events in the study group after 15 and 30 days of treatment was significantly lower than that in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Tirofiban Hydrochloride is safe and reliable in patients with non-ST-segment elevation acute syndrome due to conventional therapy. It can reduce the incidence of adverse cardiovascular events with less adverse reactions and higher value. It is suggested that Clinical.